On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

  • Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020
  • CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers
  • Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members, Dr. Waldemar Priebe, Ph.D., and Dr. Sigmund Hsu, M.D., both of whom were involved in the Phase 1 trial of Berubicin, CNS Pharmaceuticals’ lead drug candidate.

Dr. Wen is a Neurology professor at Harvard Medical School and the Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. Dr. Wen is a member of the Board of Directors of The Society for Neuro-Oncology and is also its immediate past President. An accomplished neuro-oncologist with a proven track record treating brain tumors and related neurologic complications, Dr. Wen is a graduate of University of London’s Medical College of St. Bartholomew’s Hospital. He continued his postgraduate internal medicine training with the University of London and completed his neurology residency with the Harvard-Longwood Neurology Training Program.

According to CNS Pharmaceuticals CEO John Climaco, Dr. Wen’s extensive experience in neuro-oncology will be invaluable to the company as it prepares for its upcoming Berubicin clinical trials. “The addition of Dr. Wen strongly complements our strategy to further drive the development of Berubicin as we look forward to initiating our pivotal Phase II trial in the U.S. and to working with our partner WPD Pharmaceuticals on the Phase I pediatric and Phase II adult studies in Poland,” Climaco added.

Dr. Wen’s appointment was included among the latest company updates furnished to the Securities and Exchange Commission on September 21, 2020. The investor presentation in the Form 8-K/A also announced that the company’s pivotal Phase 2 clinical trial for Berubicin in the United States is expected to begin in Q1 2021 (https://ibn.fm/MRaIq). In addition, Berubicin clinical trials in Poland (Phase 2 for adults and the first-ever Phase 1 trial for pediatric patients) are also due to begin on a similar timeline.

CNS Pharmaceuticals’ lead drug candidate is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. It is an organ targeted therapeutic that belongs to a class of cancer drugs called anthracyclines. CNS Pharmaceuticals has stated that it believes, based on limited clinical data, that Berubicin is the first drug in this class to cross the blood-brain barrier in adults, reaching the tumor cells of a patient with brain cancer.

Berubicin was developed by CNS Founder and Scientific Advisory Board member Dr. Waldemar Priebe, Ph.D., Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The development of Berubicin has been ongoing for over 15 years. The drug was granted Orphan Drug designation by the FDA for malignant gliomas in June 2020. CNS Pharmaceuticals is currently expected to make an Investigational New Drug (“IND”) submission to the FDA in Q4 2020.

In Phase 1 trials of Berubicin, conducted by Reata Pharmaceuticals (NASDAQ: RETA), 44% of GBM patients showed clinically significant response to Berubicin. A patient from the Phase 1 trial remains cancer-free following the trial treatment of Berubicin approximately 14 years ago.

CNS Pharmaceuticals plans for the Phase 2 adult trial in the United States to be adaptive, randomized, and controlled. These criteria for Phase 2 are intended to provide the data required for accelerated approval by the FDA. Additionally, the company plans to use the Phase 2 adult trial in Poland, conducted by sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1), to provide additional statistical support for the U.S. trial.

Plans are also in motion to begin Berubicin clinical trials for lymphomas, pancreatic, and ovarian cancers in 2021, which speaks to the high level of confidence CNS Pharmaceuticals has in Berubicin trials and its potential impact on the brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (https://ibn.fm/fqDvu).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered